Surrozen (NASDAQ:SRZN) Releases Quarterly Earnings Results, Misses Estimates By $9.92 EPS

Surrozen (NASDAQ:SRZN) released its quarterly earnings results on Monday. The company reported ($11.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by ($9.92), FiscalAI reports.

Surrozen Stock Down 2.3%

Shares of NASDAQ SRZN opened at $31.88 on Thursday. The business has a 50-day moving average of $25.54 and a two-hundred day moving average of $25.42. Surrozen has a 1 year low of $12.12 and a 1 year high of $37.83.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $54.00 price target (up from $44.00) on shares of Surrozen in a research note on Friday, September 25th. Cantor Fitzgerald upped their price target on Surrozen from $40.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday. William Blair assumed coverage on Surrozen in a research note on Thursday, August 20th. They issued an “outperform” rating and a $51.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, October 15th. Finally, Zacks Research raised shares of Surrozen from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Surrozen currently has an average rating of “Moderate Buy” and an average target price of $61.75.

Surrozen Company Profile

Surrozen, Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation. The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues.